Stock Research for ARQL

ARQL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARQL Stock Chart & Research Data

The ARQL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARQL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARQL Due diligence Resources & Stock Charts

The ARQL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARQL Detailed Price Forecast - CNN Money CNN View ARQL Detailed Summary - Google Finance
Yahoo View ARQL Detailed Summary - Yahoo! Finance Zacks View ARQL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ARQL Trends & Analysis - Trade-Ideas Barrons View ARQL Major Holders - Barrons
NASDAQ View ARQL Call Transcripts - NASDAQ Seeking View ARQL Breaking News & Analysis - Seeking Alpha
Spotlight View ARQL Annual Report - CompanySpotlight.com OTC Report View ARQL OTC Short Report - OTCShortReport.com
TradeKing View ARQL Fundamentals - TradeKing Charts View ARQL SEC Filings - Bar Chart
WSJ View Historical Prices for ARQL - The WSJ Morningstar View Performance/Total Return for ARQL - Morningstar
MarketWatch View the Analyst Estimates for ARQL - MarketWatch CNBC View the Earnings History for ARQL - CNBC
StockMarketWatch View the ARQL Earnings - StockMarketWatch MacroAxis View ARQL Buy or Sell Recommendations - MacroAxis
Bullish View the ARQL Bullish Patterns - American Bulls Short Pains View ARQL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ARQL Stock Mentions - StockTwits PennyStocks View ARQL Stock Mentions - PennyStockTweets
Twitter View ARQL Stock Mentions - Twitter Invest Hub View ARQL Investment Forum News - Investor Hub
Yahoo View ARQL Stock Mentions - Yahoo! Message Board Seeking Alpha View ARQL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ARQL - SECform4.com Insider Cow View Insider Transactions for ARQL - Insider Cow
CNBC View ARQL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARQL - OTC Markets
Yahoo View Insider Transactions for ARQL - Yahoo! Finance NASDAQ View Institutional Holdings for ARQL - NASDAQ


Stock Charts

FinViz View ARQL Stock Insight & Charts - FinViz.com StockCharts View ARQL Investment Charts - StockCharts.com
BarChart View ARQL Stock Overview & Charts - BarChart Trading View View ARQL User Generated Charts - Trading View




Latest Financial News for ARQL


ArQule Inc (NASDAQ:ARQL) Is Expected To Breakeven
Posted on Wednesday September 19, 2018

ArQule Inc’s (NASDAQ:ARQL): ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The US$548.4m market-cap company’s loss lessensRead More...


Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)
Posted on Thursday September 13, 2018

ArQule, Inc. (ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related Overgrowth Spectrum (PROS), a group of related, ultra-rare genetic disorders characterized by excessive tissue growth in various parts of the body. The FDA’s Fast Track program aims to expedite the development and review of drugs which treat serious or life-threatening conditions and have demonstrated the potential to address unmet clinical needs. Miransertib has already been granted Rare Pediatric Disease Designation by the FDA and Orphan Designation by the FDA and European Medicines Agency in the rare overgrowth disease, Proteus syndrome.


Implied Volatility Surging for ArQule (ARQL) Stock Options
Posted on Wednesday September 05, 2018

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.


ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018
Posted on Thursday August 30, 2018

ArQule, Inc. today announced that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel discussions at the B.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.